Earnings ·
Evogene Ltd. reported second quarter and first half 2026 financial results on August 18, 2026
EVGNEvogene Ltd.
Evogene Ltd. reported second quarter and first half 2026 financial results on August 18, 2026. The company reduced its net loss to approximately $1.8 million for the quarter, down from $4.7 million in the prior year period. Cash burn is expected to decline to $8.5–$9.5 million in 2026, compared with $14.4 million in 2025. Evogene raised approximately $11.1 million in new capital since early 2025 and holds $9.3 million in cash as of June 30, 2026. The company expanded its virtual chemical space to 110 billion molecules and integrated autonomous AI Agents via a partnership with Google Cloud. It also established six active drug development collaborations and advanced internal programs toward lead optimization. Evogene operates in the computational chemistry industry, specializing in the generative design of small molecules for pharmaceutical and agricultural applications.